Peter Achenbach

List of Publications by Year
in descending order

79 papers	4,164 citations	109321 35 h-index	118850 62 g-index
86 all docs	86 docs citations	86 times ranked	3547 citing authors

#	Article	IF	Citations
1	Immune response differs between intralymphatic or subcutaneous administration of GADâ€alum in individuals with recent onset type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2022, 38, e3500.	4.0	8
2	Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children. Diabetes Care, 2022, 45, 160-168.	8.6	8
3	Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial). Acta Diabetologica, 2022, 59, 687-696.	2.5	9
4	Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany. Diabetes Care, 2022, 45, 837-844.	8.6	14
5	Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories. Nature Communications, 2022, 13, 1514.	12.8	16
6	Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a caseâ€“control study. Diabetologia, 2022, , .	6.3	3
7	A classification and regression tree analysis identifies subgroups of childhood type 1 diabetes. EBioMedicine, 2022, 82, 104118.	6.1	21
8	A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med, 2021, 2, 149-163.e4.	4.4	85
9	Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia, 2021, 64, 1079-1092.	6.3	31
10	Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open, 2021, 11, e052449.	1.9	15
11	A hormone complex of FABP4 and nucleoside kinases regulates islet function. Nature, 2021, 600, 720-726.	27.8	36
12	Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnology Advances, 2020, 39, 107359.	11.7	34
13	Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients. Frontiers in Immunology, 2020, 11, 564921.	4.8	19
14	Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA - Journal of the American Medical Association, 2020, 323, 339.	7.4	139
15	Modeling Disease Progression Trajectories from Longitudinal Observational Data. AMIA ... Annual Symposium proceedings, 2020, 2020, 668-676.	0.2	3
16	Birth and coming of age of islet autoantibodies. Clinical and Experimental Immunology, 2019, 198, 294-305.	2.6	35
17	Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance. Clinical Chemistry, 2019, 65, 1141-1152.	3.2	62
18	Age, HLA, and Sex Define a Marked Risk of Organ-Specific Autoimmunity in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1684-1691.	8.6	12

#	Article	IF	Citations
19	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open, 2019, 9, e028578.	1.9	62
20	Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children â€" evaluation of the Fr1da study. Zeitschrift Fur Gesundheitswissenschaften, 2019, 27, 553-560.	1.6	3
21	Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. Diabetes, 2019, 68, 119-130.	0.6	28
22	Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia, 2018, 61, 1644-1649.	6.3	42
23	A novel LIPS assay for insulin autoantibodies. Acta Diabetologica, 2018, 55, 263-270.	2.5	36
24	A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. Science Translational Medicine, 2018, 10, .	12.4	49
25	Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia, 2018, 61, 1484-1490.	6.3	32
26	Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. Contemporary Clinical Trials Communications, 2018, 11, 170-173.	1.1	9
27	Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia, 2018, 61, 2252-2258.	6.3	51
28	Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-11.	2.3	23
29	Fasting hypoglycemia is associated with disease progression in presymptomatic early stage type 1 diabetes. Pediatric Diabetes, 2018, 19, 1238-1242.	2.9	1
30	Peptide serum markers in islet autoantibody-positive children. Diabetologia, 2017, 60, 287-295.	6.3	24
31	Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome, 2016, 4, 17.	11.1	100
32	Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open, 2016, 6, e011144.	1.9	89
33	3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technology and Therapeutics, 2016, 18, 687-693.	4.4	27
34	3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. Clinica Chimica Acta, 2016, 462, 60-64.	1.1	25
35	A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children. Diabetologia, 2016, 59, 2172-2180.	6.3	38
36	Type 1 diabetes vaccine candidates promote human Foxp3+Treg induction in humanized mice. Nature Communications, 2016, 7, 10991.	12.8	99

#	Article	IF	Citations
37	Reactivity to N-Terminally Truncated GAD65(96â€“585) Identifies GAD Autoantibodies That Are More Closely Associated With Diabetes Progression in Relatives of Patients With Type 1 Diabetes. Diabetes, 2015, 64, 3247-3252.	0.6	27
38	Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia, 2015, 58, 411-413.	6.3	29
39	Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes. Diabetes, 2015, 64, 3239-3246.	0.6	44
40	Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2015, 313, 1541.	7.4	174
41	Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes. Diabetologia, 2015, 58, 2317-2323.	6.3	71
42	GAD Autoantibody Affinity in Adult Patients With Latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial. Diabetes Care, 2014, 37, 1675-1680.	8.6	39
43	Compromised Gut Microbiota Networks in Children With Anti-Islet Cell Autoimmunity. Diabetes, 2014, 63, 2006-2014.	0.6	154
44	A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes. Diabetes, 2014, 63, 2538-2550.	0.6	261
45	GAD autoantibody affinity in schoolchildren from the general population. Diabetologia, 2014, 57, 1911-1918.	6.3	22
46	Soluble interleukin-2 receptor alpha in preclinical type 1 diabetes. Acta Diabetologica, 2014, 51, 517-518.	2.5	4
47	HLA-typing, clinical, and immunological characterization of youth with type 2 diabetes mellitus phenotype from the German/Austrian DPV database. Pediatric Diabetes, 2013, 14, 562-574.	2.9	23
48	IA-2 autoantibody affinity in children at risk for type 1 diabetes. Clinical Immunology, 2012, 145, 224-229.	3.2	16
49	A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes. Genes and Immunity, 2012, 13, 549-555.	4.1	63
50	10 Autoimmunity in diabetes mellitus. , 2012, , 119-138.		0
51	Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia, 2012, 55, 1937-1943.	6.3	209
52	Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. Diabetologia, 2012, 55, 1978-1984.	6.3	39
53	Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty - TEENDIAB: study design. Pediatric Diabetes, 2012, 13, 419-424.	2.9	30
54	Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. Journal of Autoimmunity, 2011, 37, 3-7.	6.5	65

#	Article	IF	Citations
55	Insulin autoantibodies with high affinity to the bovine milk protein alpha casein. Clinical and Experimental Immunology, 2011, 164, 42-49.	2.6	7
56	Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method. Diabetologia, 2011, 54, 699-700.	6.3	2
57	Diabetes Antibody Standardization Program. Diabetes Care, 2011, 34, 2410-2412.	8.6	17
58	Age- and Islet Autoimmunityâ€“Associated Differences in Amino Acid and Lipid Metabolites in Children at Risk for Type 1 Diabetes. Diabetes, 2011, 60, 2740-2747.	0.6	96
59	A simplified method to assess affinity of insulin autoantibodies. Clinical Immunology, 2010, 137, 415-421.	3.2	10
60	Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia, 2009, 52, 1881-1888.	6.3	166
61	Autoantibodies to IA-2Î² improve diabetes risk assessment in high-risk relatives. Diabetologia, 2008, 51, 488-492.	6.3	47
62	Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Current Diabetes Reports, 2008, 8, 87-93.	4.2	71
63	Translating Mucosal Antigen based Prevention of Autoimmune Diabetes to Human. Novartis Foundation Symposium, 2008, 292, 187-201.	1.1	5
64	Tracing the Pathogenesis of Type 1 Diabetes: A Report on the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD). Review of Diabetic Studies, 2008, 5, 171-174.	1.3	1
65	GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 Diabetes. Diabetes, 2007, 56, 1527-1533.	0.6	81
66	Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clinical Immunology, 2007, 122, 85-90.	3.2	50
67	Identification of insulin autoantibodies of IgA isotype that preferentially target non-human insulin. Clinical Immunology, 2007, 124, 77-82.	3.2	8
68	Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia, 2006, 49, 2969-2976.	6.3	42
69	Autoimmunity in Type 1 Diabetes mellitus. , 2005, 10, 57-71.		0
70	In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia, 2005, 48, 1830-1832.	6.3	44
71	Predicting type 1 diabetes. Current Diabetes Reports, 2005, 5, 98-103.	4.2	48
72	Natural History of Type 1 Diabetes. Diabetes, 2005, 54, S25-S31.	0.6	223

#	Article	IF	Citations
73	Diabetes-related antibodies in euglycemic subjects. Best Practice and Research in Clinical Endocrinology and Metabolism, 2005, 19, 101-117.	4.7	9
74	Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics. Diabetes, 2004, 53, 384-392.	0.6	243
75	Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Journal of Clinical Investigation, 2004, 114, 589-597.	8.2	173
76	Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Journal of Clinical Investigation, 2004, 114, 589-597.	8.2	120
77	Modulating the Autoimmune Response in Type 1 Diabetes: A Report on the 64th Scientific Sessions of the ADA, June 2004, Orlando, FL, USA. Review of Diabetic Studies, 2004, 1, 137-137.	1.3	0
78	Spontaneous Peripheral T-cell Responses to the IA-2Î² (Phogrin) Autoantigen in Young Nonobese Diabetic Mice. Journal of Autoimmunity, 2002, 19, 111-116.	6.5	15
79	Antibodies to the Tyrosine Phosphatase-like Protein IA-2 are highly associated with IDDM, but not with Autoimmune Endocrine Diseases or Stiff Man Syndrome. Autoimmunity, 1997, 25, 203-211.	2.6	28